A Randomized, Single-Blind Controlled Trial Comparing Two Needle Agitation Strategies During Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Diagnostic Yield in Patients With Enlarged Mediastinal Lymph Nodes
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Phan Quang Hieu
- Enrollment
- 180
- Locations
- 2
- Primary Endpoint
- Diagnostic Yield of EBUS-TBNA
Overview
Brief Summary
The goal of this clinical trial is to learn whether the number of needle agitations during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) affects diagnostic yield in patients with enlarged mediastinal lymph nodes. The study will also evaluate tissue sample quality and the safety of different needle agitation strategies.
The main questions it aims to answer are:
Does the number of needle agitations improve diagnostic yield? Does a higher number of needle agitations increase tissue core length and specimen adequacy? Are there differences in procedure-related complications between the two needle agitation strategies? Researchers will compare two needle agitation strategies during EBUS-TBNA to see if one approach provides better diagnostic performance, improved sample quality, and similar procedural safety.
Participants will:
- Undergo EBUS-TBNA as part of their clinical evaluation
- Be randomly assigned to one of two needle agitation strategies
- Have tissue samples measured for core length and assessed for diagnostic adequacy
- Be monitored for procedure-related complications
Detailed Description
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has become the standard minimally invasive modality for sampling mediastinal lymph nodes in patients with suspected thoracic malignancies and benign lymphadenopathies. Despite its widespread adoption and high overall diagnostic performance, variability in procedural techniques may contribute to heterogeneity in specimen quality and diagnostic yield.
Among procedural factors, the number of needle agitations performed during each needle pass represents a modifiable technical variable that may influence tissue acquisition. Increased needle agitation may theoretically enhance tissue yield and core length by promoting mechanical dissection of nodal tissue; however, excessive agitation may also increase blood contamination, reduce sample interpretability, or elevate procedural trauma risk. Conversely, fewer agitations may limit tissue disruption but potentially result in inadequate sampling. Currently, there is no high-level evidence establishing an optimal agitation strategy, and operator-dependent variability remains common in clinical practice.
This randomized, single-blind controlled trial is designed to compare two predefined needle agitation strategies during EBUS-TBNA. By standardizing all other procedural variables, the study aims to isolate the effect of agitation number on diagnostic performance. Objective procedural metrics, including measured tissue core length and specimen adequacy, will be systematically assessed to provide quantitative evaluation of sample quality. Procedural safety outcomes will also be monitored to evaluate whether differences in agitation strategy influence complication rates.
The results of this trial are expected to provide evidence-based data to support technical standardization of EBUS-TBNA and to inform procedural guidelines aimed at optimizing diagnostic efficiency while maintaining safety.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Diagnostic
- Masking
- Double (Participant, Outcomes Assessor)
Masking Description
The pathologists evaluating the tissue specimens will be blinded to group allocation. Participants will not be informed of the assigned needle agitation strategy.
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years
- •Presence of enlarged mediastinal or hilar lymph nodes requiring diagnostic evaluation on chest computed tomography (CT), defined as short-axis diameter ≥ 10 mm measured on axial images
- •Clinical indication for EBUS-TBNA
- •Ability to provide written informed consent
Exclusion Criteria
- •Uncorrected coagulation disorders (platelet count \< 100,000/mm³; International normalized ratio (INR) \> 1.5; or prothrombin time \< 50% of control)
- •Acute myocardial infarction within the preceding 4 weeks or ongoing unstable angina
- •Significant upper airway obstruction (benign or malignant) with ≥ 50% reduction in tracheal lumen diameter
- •Hemodynamic instability (e.g., persistent hypotension, significant arrhythmia, or need for vasopressors)
- •Respiratory failure refractory to oxygen therapy, defined as sustained Peripheral oxygen saturation (SpO₂) ≤ 90% despite supplemental oxygen
- •Intractable cough precluding bronchoscopy
- •History of severe allergy to local anesthetics or sedative agents used during the procedure
- •Refusal or inability to provide informed consent
Arms & Interventions
10 to <30 Agitations (Target 20)
Participants will undergo endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) using a low-range needle agitation strategy: 10 to fewer than 30 needle agitations per needle pass, with a target of approximately 20 agitations. All other procedural parameters, including needle type, number of passes, suction technique, and specimen handling, will be standardized.
Intervention: Needle Agitation Strategy During EBUS-TBNA (Procedure)
30 to 60 Agitations (Target 45-50)
Participants will undergo endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) using a high-range needle agitation strategy: 30 to 60 needle agitations per needle pass, with a target of approximately 45 to 50 agitations. All other procedural parameters, including needle type, number of passes, suction technique, and specimen handling, will be standardized.
Intervention: Needle Agitation Strategy During EBUS-TBNA (Procedure)
Outcomes
Primary Outcomes
Diagnostic Yield of EBUS-TBNA
Time Frame: Within 7-14 days after the procedure
Proportion of cases in which EBUS-TBNA provides a definitive histopathological diagnosis based on tissue specimens obtained during the procedure.
Secondary Outcomes
- Tissue Core Length(Immediately after the procedure)
Investigators
Phan Quang Hieu
Principal Investigator
University Medical Center Ho Chi Minh City (UMC)